Kyoto University · Medicine
Professor Tomoaki Yoh's research lab specializes in hepatobiliary and pancreatic surgery, with a primary focus on improving long-term outcomes for patients with hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). The lab investigates patient selection criteria for repeat surgery, resectability assessment, and multimodal treatment strategies to enhance survival in advanced or recurrent disease. Key research directions include identifying prognostic factors, predicting lymph node metastasis, and optimizing surgical and adjuvant therapies for selected patients.
Figures are computed from collected data and may differ slightly.
Surgery for recurrent HCC may yield long-term survival for not only IHR but also for EHR in selected patients.
Repeat surgery for recurrent ICC with an appropriate selection can be associated with prolonged survival. Regarding the feasibility, nodal status, number of tumors on the primary tumor, and time to recurrence may be considered as selection criteria.
When macroscopic curative resection is possible, surgical resection can be justified for some advanced ICC patients with IM, VI, or LM.
We proposed a preoperative criterion for predicting LN metastasis, giving rise to the identification of ICC patients who showed a low-risk of LN metastasis.
Our proposal of resectability for HCC allows for stratifying survival outcomes of HCC and may help to determine treatment strategy.
ICC patients, particularly those with N1 disease, achieved significant survival improvements that were partly attributable to patient selection, adjuvant chemotherapy, and multimodal treatment after recurrence.
Even in the era of multidisciplinary strategy, high tumor SUVmax still represents poor prognosis in patients undergoing surgery for ICC. These patients, therefore, would probably be required more effective strategies.
Laparoscopic surgery has become an increasingly popular alternative approach to open surgery, resulting in a paradigm shift in liver surgery. Although laparoscopic liver resection (LLR) was initially indicated for small benign and peripheral tumors, at present more than half of LLRs are performed in malignant tumors. Several studies have reported the feasibility of LLR in malignant disease and suggested various short-term benefits compared to open liver resection, including decreased blood loss
Serum NRDC, a possible surrogate marker reflecting the EMT state in primary tumors, predicts the outcome of ICC after surgical resection.
Laparoscopic liver surgery has gained wide acceptance resulting in a paradigm shift of liver surgery. Technical innovations and accumulation of surgeon's experience have allowed laparoscopic liver resection (LLR) to become an effective procedure with favorable peri- and post-operative outcomes. Through the overall process of LLR, liver parenchymal transection remains the most critical step with the aim of minimizing blood loss and secures the appropriate cutting line, i.e., securing major vessel
Open papers in the app to read, cite, and organize with AI.
